The race to unravel Huntington's disease (HD) has led scientists to a fascinating yet perplexing phenomenon: why do symptoms appear later in life, despite the genetic mutation being present from birth? This enigma, known as somatic instability, has sparked a flurry of research, with a recent study from Dr. Jeff Carroll's lab at the University of Washington taking center stage.
Genes, Proteins, and the HD Mystery
Genes, the blueprints of life, are transcribed into messenger molecules called mRNA, which are then translated into proteins. In HD, the huntingtin gene (HTT) contains an extra code (CAG) that repeats excessively, leading to an abnormal protein. But here's the twist: these CAG repeats can expand further over time, a process called somatic instability, potentially delaying the onset of HD symptoms.
The Hunt for a Cure: Targeting Huntingtin
Numerous clinical trials are focused on reducing the huntingtin protein, but a critical question remains: will this slow down the CAG repeat expansion? While somatic instability is a prime suspect for the delayed onset, it's a correlation yet to be proven. The University of Washington team decided to investigate this mystery.
ASOs: More Than Meets the Eye
Using Antisense Oligonucleotides (ASOs), a therapy that targets mRNA, the researchers lowered HTT levels in mice. Surprisingly, ASOs not only reduced HTT protein but also slowed CAG repeat growth by 50%. This finding is significant because ASOs are already being tested in clinical trials for HD.
But here's where it gets controversial: the researchers suspected that ASOs might be disrupting transcription, the process of making mRNA from DNA. They found that higher transcription rates led to faster CAG buildup. This led them to explore two theories:
- The Protein Theory: The HTT protein itself causes somatic instability, and reducing its production slows it down.
- The Transcription Theory: The act of transcribing the HTT gene triggers somatic instability, and lowering transcription reduces it.
To test these, they used siRNA, which lowers HTT protein but doesn't affect transcription. Interestingly, siRNA had no effect on somatic instability, suggesting that ASOs work by disrupting transcription, not just lowering protein levels.
A Road to Understanding
Imagine the HTT gene as a road with trucks carrying packages (mRNA). Over time, the road develops potholes (CAG repeats). Reducing packages with siRNA doesn't fix the road; it just reduces the load. But ASOs reduce the number of trucks, slowing down the road's deterioration. This analogy helps us grasp the difference between siRNA and ASOs.
Switching Genes On and Off
The team then used a clever mouse model where HTT transcription could be switched on or off with a chemical. When transcription was turned off, somatic instability slowed. This, along with the ASO experiments, suggested that transcription plays a role in somatic instability.
Zinc Finger Proteins: Roadblocks to the Rescue
While switching genes on and off with chemicals is intriguing, it's not practical for humans. So, the researchers turned to Zinc Finger Proteins (ZFPs), which directly block transcription by binding to CAG repeats. In a mouse brain experiment, ZFPs that blocked transcription reduced somatic instability by 70%. Even ZFPs that didn't block transcription had a 42% reduction. This is promising, as completely shutting down HTT transcription might be harmful since HTT has essential functions.
The Therapeutic Journey
These findings indicate that reducing HTT transcription might slow CAG growth and decrease toxic HTT protein. However, we must remember that somatic instability's role in HD onset is still a hypothesis. Moreover, altering transcription could have unforeseen consequences. While therapies targeting transcription look encouraging, we need to proceed with caution.
Clinical trials with ASOs are ongoing, and ZFP-based therapies are in development. However, these studies use genetically modified mice with extreme CAG repeats, which may not accurately represent human biology. The safety and effectiveness of these therapies in humans remain unknown, leaving us with more questions than answers.
The HD Puzzle: Solved?
In summary, somatic instability, caused by expanding CAG repeats in the HTT gene, might contribute to HD's delayed onset. ASO treatments work by reducing HTT transcription, not just protein levels. Various experiments confirm that lower HTT transcription leads to slower CAG growth. While these therapies show promise, it's unclear if they will change HD onset in humans.
The journey to understanding and treating HD is complex, and each discovery brings us closer to the ultimate goal of a cure. But will these therapies be the missing piece of the puzzle? Only time and further research will tell.
